Health Care [ 4/12 ] | Pharmaceuticals [ 10/74 ]
NASDAQ | Common Stock
scPharmaceuticals Inc., a pharmaceutical company, focuses on developing and commercializing products to optimize the delivery of infused therapies and patient care.
The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for the treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.
Its product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity and drug-device combination product candidate consisting of a prefilled syringe containing SCP-111 preloaded into a mechanical autoinjector.
The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 12, 25 | -0.37 Decreased by -2.78% | -0.28 Decreased by -29.82% |
| Mar 11, 25 | -0.31 Increased by +10.31% | -0.39 Increased by +19.51% |
| Nov 6, 24 | -0.28 Increased by +31.71% | -0.30 Increased by +6.67% |
| Aug 8, 24 | -0.44 Decreased by -22.22% | -0.40 Decreased by -10.00% |
| May 14, 24 | -0.36 Decreased by -20.00% | -0.44 Increased by +18.18% |
| Mar 13, 24 | -0.35 Decreased by -16.67% | -0.42 Increased by +16.67% |
| Nov 8, 23 | -0.41 Decreased by -10.81% | -0.36 Decreased by -13.89% |
| Aug 10, 23 | -0.36 Decreased by -2.86% | -0.37 Increased by +2.70% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 11.75 M Increased by +92.59% | -19.74 M Decreased by -39.93% | Decreased by -167.99% Increased by +27.34% |
| Dec 31, 24 | 12.15 M Increased by +99.31% | -18.84 M Decreased by -36.44% | Decreased by -155.10% Increased by +31.54% |
| Sep 30, 24 | 10.03 M Increased by +164.12% | -35.10 M Decreased by -124.54% | Decreased by -350.14% Increased by +14.98% |
| Jun 30, 24 | 8.05 M Increased by +391.70% | -17.09 M Decreased by -20.74% | Decreased by -212.19% Increased by +75.44% |
| Mar 31, 24 | 6.10 M Increased by +195.78% | -14.11 M Decreased by -9.99% | Decreased by -231.20% Increased by +62.82% |
| Dec 31, 23 | 6.10 M Increased by +N/A% | -13.81 M Decreased by -41.49% | Decreased by -226.57% Decreased by N/A% |
| Sep 30, 23 | 3.80 M Increased by +N/A% | -15.63 M Decreased by -51.36% | Decreased by -411.85% Decreased by N/A% |
| Jun 30, 23 | 1.64 M Increased by +N/A% | -14.15 M Decreased by -41.92% | Decreased by -864.10% Decreased by N/A% |